Speakers:
Mishka Terplan, MD, MPH, FACOG, DFASAM has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.
Planners and other Administrative Support:
Sara Dugan, PharmD, John Ellis, MSW, LICDC-CS, ICCS, Christina Delos Reyes, MD, and Stacey Gardner-Buckshaw, PhD have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.
Sara Dugan, PharmD has indicated the presentation may include discussion of any off-label uses of a product.
Explanation Given: There are limited treatment options that have FDA approval for the indication of aggression therefore discussion of treatment is usually inclusive of off label treatments.